Tranexamic Acid in Hip Fracture Surgery

Hip Fracture Clinical Trial

Official title:

Effectiveness of Tranexamic Acid (TXA) in Reducing Blood Loss in Hip Fracture Surgery

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02736383
• Other study ID #: 2016-060
• Status: Completed
• Start date: May 2016
• Est. completion date: July 2017

Study information

• Verified date: September 2023
• Source: Spectrum Health Hospitals
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

To determine if TXA utilization is effective at reducing transfusion rates in elderly patients undergoing surgery for treatment of a hip fractures.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 142
• Est. completion date: July 2017
• Est. primary completion date: July 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 65 Years and older

Eligibility

Inclusion Criteria:

• Acute, isolated, unilateral femoral neck, intertrochanteric, and per trochanteric hip fractures confirmed by anteroposterior/lateral hip radiographs, computed tomography, or magnetic resonance imaging.

• Age 65 and older

• Low energy mechanism of injury

• Hip fracture fixation performed within 48 hours

• English speaking

• Anticipated medical optimization for operative fixation

• No other major trauma

Exclusion Criteria:

• Retained hardware around the affected hip

• Infection around the affected hip

• Transfer patients with a length of stay > 24 hours at the transferring hospital

• Diagnosis of deficient natural anticoagulation

• Known congenital thrombophilia (Deficiency of Protein C, S, Antithrombin)

• Known allergy to TXA

• Patients undergoing percutaneous pinning of the hip fracture

Related Conditions & MeSH terms

• Fractures, Bone
• Hip Fracture
• Hip Fractures

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Spectrum Health Hospitals

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Blood Transfusion Rate	Blood transfusion rates during the patients hospital stay will be assessed.	6 weeks
Secondary	Hospital Length of stay	The patients length of stay in the hospital will be determined.	6 weeks
Secondary	Post operative complications	Post operative complications will be assessed through the 6 weeks.	6 weeks
Secondary	Hospitalization costs	Economic evaluation for inpatient and re-admission will be assessed.	6 weeks